New drug cocktail aims to fight tough lung cancer
NCT ID NCT07640932
First seen Jun 12, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This study tests whether combining two chemotherapy drugs—lurbinectedin and paclitaxel—works better than paclitaxel alone for people with advanced small cell lung cancer that has returned or worsened after initial treatment. About 69 adults will be randomly assigned to one of the two treatment groups. The main goal is to see if the combination shrinks more tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, SMALL CELL LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lurbinectedin and paclitaxel
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced small cell lung cancer whose disease has worsened after initial chemotherapy.
What could go wrong
This is a small, early-phase (Phase 2) trial, so results may not confirm benefit. The combination may cause more side effects than paclitaxel alone, and not all patients may respond.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.